DENV4 Antibodies Targeting Hexameric NS1 Epitopes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current dengue virus serotype 4 (DENV4) NS1 antigen detection tests have low sensitivity due to cross-reactive monoclonal antibodies and poor bio-accessibility of epitopes, leading to ineffective detection of DENV4 infections, particularly in secondary infections and patients with low NS1 expression levels.
Innovation Solution
Development of DENV4-specific antibodies and assays that target hexameric NS1 epitopes, using a solubility and stability tag to produce a stable and multimeric NS1 complex for immunization and antibody production, enabling specific detection of DENV4 NS1 in serum samples.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If cross-reactive monoclonal antibodies are used for NS1 detection, then the assay can detect multiple DENV serotypes, but the sensitivity for DENV4 detection deteriorates
Solution Approach 1:
The patent divides the universal anti-NS1 antibody approach into serotype-specific antibody segments. By developing separate monoclonal antibodies for each DENV serotype (DENV1, DENV2, DENV3, and DENV4), the assay can maintain high sensitivity for each serotype while using a multiplex format to detect all four serotypes simultaneously, resolving the contradiction between versatility and precision.
Solution Approach 2:
The patent applies local quality by using serotype-specific epitopes on the NS1 protein. Each monoclonal antibody is designed to recognize a specific epitope that is uniquely accessible or predominant on its target serotype's NS1 protein, allowing the assay to maintain high sensitivity for DENV4 while also detecting other serotypes with their respective specific antibodies.
2Ease of manufacture
If existing NS1 ELISA kits are used, then the test can be performed with standard reagents, but the sensitivity for DENV4 and secondary infections deteriorates
Solution Approach 1:
The patent changes the critical parameter of antibody specificity from cross-reactive to serotype-specific. By reformulating the ELISA kit to include DENV4-specific monoclonal antibodies instead of universal cross-reactive antibodies, the sensitivity for DENV4 detection is significantly improved while maintaining the ease of manufacture through standard ELISA methodology.
3Stability of the object's composition
If NS1 protein is used as detection target, then the protein is highly conserved and group-specific, but the bio-accessibility of epitopes for DENV4 deteriorates
Solution Approach 1:
The patent applies local quality by focusing on specific epitopic regions of the NS1 protein that are locally accessible or exposed on the surface of DENV4-infected cells. By selecting monoclonal antibodies that target these specifically accessible epitopes rather than trying to access all conserved regions, the assay achieves high sensitivity for DENV4 while maintaining recognition of the conserved NS1 protein structure.
Data Source
AI summary
The present disclosure relates to polypeptides that specifically bind to Dengue virus non¬structural protein 1, including antibodies and fragments thereof. The antibody or antigen-binding fragment thereof may specifically bind Dengue virus (DENV) serotype 4 and include: a heavy chain variable region that comprises at least one CDR amino acid sequence selected from the group consisting of: SGYNWH, YIH YS GGTN YNPS LKS, RTGTVPFAY, SYVMH, YLNPYNDDTKYNEKFKG, and GPPYALDY. The present disclosure further relates to methods of producing the polypeptides of the present disclosure, methods of diagnosing DENV, and methods of treating a DENV infection.